117 related articles for article (PubMed ID: 38310381)
21. Assessment of Ultrasound Features and BI-RADS Categories of Malignant Breast Masses in Women ≤40.
Gity M; Jafari M; Olfatbakhsh A; Rezaei Kalantari K; Hashemi E; Sari F
Arch Iran Med; 2021 May; 24(5):383-389. PubMed ID: 34196203
[TBL] [Abstract][Full Text] [Related]
22. Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer.
Choi WJ; Sim H; Kim HJ; Cha JH; Shin HJ; Chae EY; Kim HH
Acta Radiol; 2021 Dec; 62(12):1592-1600. PubMed ID: 33302692
[TBL] [Abstract][Full Text] [Related]
23. Solitary Dilated Ducts Revisited: Malignancy Rate and Implications for Management.
Panigrahi B; Fernandes K; Mullen LA; Oluyemi E; Myers KS; Philip M; Carlo PD; Ambinder EB
Acad Radiol; 2023 May; 30(5):807-813. PubMed ID: 36115737
[TBL] [Abstract][Full Text] [Related]
24. A New Practical Decision Rule to Better Differentiate BI-RADS 3 or 4 Breast Masses on Breast Ultrasound.
Pfob A; Barr RG; Duda V; Büsch C; Bruckner T; Spratte J; Nees J; Togawa R; Ho C; Fastner S; Riedel F; Schaefgen B; Hennigs A; Sohn C; Heil J; Golatta M
J Ultrasound Med; 2022 Feb; 41(2):427-436. PubMed ID: 33942358
[TBL] [Abstract][Full Text] [Related]
25. Can second-look ultrasound downgrade MRI-detected lesions? A retrospective study.
Kolta M; Clauser P; Kapetas P; Bernathova M; Pinker K; Helbich TH; Baltzer PAT
Eur J Radiol; 2020 Jun; 127():108976. PubMed ID: 32339982
[TBL] [Abstract][Full Text] [Related]
26. Value of contrast-enhanced malignancy imaging features in secondary grade diagnosis of BI-RADS-US type 4 breast lesions.
Gao J; Han W; Ai Si Mu Tu La DLMT; Hou X; Li ZM; Song T
Tumori; 2021 Oct; 107(5):424-431. PubMed ID: 33124515
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of classification of breast ultrasound findings based on criteria used for BI-RADS.
Heinig J; Witteler R; Schmitz R; Kiesel L; Steinhard J
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):573-8. PubMed ID: 18421795
[TBL] [Abstract][Full Text] [Related]
28. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
[TBL] [Abstract][Full Text] [Related]
29. [Retrospective analysis of BI-RADS 4 and 5 lesions additionally detected by breast MRI].
Jiang L; Gao JY; Xu ZJ; He SR; Hua B
Zhonghua Wai Ke Za Zhi; 2023 Feb; 61(2):100-106. PubMed ID: 36720618
[No Abstract] [Full Text] [Related]
30. Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions?
Boisserie-Lacroix M; Ziadé C; Hurtevent-Labrot G; Ferron S; Brouste V; Lippa N
Breast; 2016 Jun; 27():1-7. PubMed ID: 27212693
[TBL] [Abstract][Full Text] [Related]
31. Do clinical and radiologic features help predict malignancy of B3 breast lesions without epithelial atypia (B3a)?
Bednarova I; Londero V; Linda A; Girometti R; Lorenzon M; Bednarova S; Zuiani C
Radiol Med; 2018 Nov; 123(11):809-817. PubMed ID: 29974332
[TBL] [Abstract][Full Text] [Related]
32. Comparison of
Liu H; Zhan H; Sun D
BMC Cancer; 2020 May; 20(1):463. PubMed ID: 32448217
[TBL] [Abstract][Full Text] [Related]
33. ShearWave™ Elastography BE1 multinational breast study: additional SWE™ features support potential to downgrade BI-RADS®-3 lesions.
Schäfer FK; Hooley RJ; Ohlinger R; Hahne U; Madjar H; Svensson WE; Balu-Maestro C; Juhan V; Athanasiou A; Mundinger A; Order B; Locatelli M; Cosgrove D; Wolf OJ; Henry JP; Moutfi M; Gay JM; Cohen-Bacrie C
Ultraschall Med; 2013 Jun; 34(3):254-9. PubMed ID: 23709241
[TBL] [Abstract][Full Text] [Related]
34. Application of contrast-enhanced ultrasound in the diagnosis of small breast lesions.
Du YR; Wu Y; Chen M; Gu XG
Clin Hemorheol Microcirc; 2018; 70(3):291-300. PubMed ID: 29710688
[TBL] [Abstract][Full Text] [Related]
35. Risk of malignancy in palpable solid breast masses considered probably benign or low suspicion: implications for management.
Giess CS; Smeglin LZ; Meyer JE; Ritner JA; Birdwell RL
J Ultrasound Med; 2012 Dec; 31(12):1943-9. PubMed ID: 23197547
[TBL] [Abstract][Full Text] [Related]
36. [Performance of users in tropical areas with the BI-RADS classification of breast lesions for predicting malignancy].
Gonsu Kamga JE; Moifo B; Sando Z; Guegang Goudjou E; Nko'o Amvene S; Gonsu Fotsin J
Med Sante Trop; 2013; 23(4):439-44. PubMed ID: 24334372
[TBL] [Abstract][Full Text] [Related]
37. Color-map virtual touch tissue imaging (CMV) combined with BI-RADS for the diagnosis of breast lesions.
Lian KM; Lin T
J Xray Sci Technol; 2022; 30(3):447-457. PubMed ID: 35147574
[TBL] [Abstract][Full Text] [Related]
38. Breast Imaging-Reporting and Data System (BI-RADS) classification in 51 excised palpable pediatric breast masses.
Koning JL; Davenport KP; Poole PS; Kruk PG; Grabowski JE
J Pediatr Surg; 2015 Oct; 50(10):1746-50. PubMed ID: 25783351
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic value of BI-RADS grade 3 to 5 for breast masses is correlated with the expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2.
He T; Shi T; Luo W; Ju Y; Li R
Medicine (Baltimore); 2023 Jun; 102(26):e33208. PubMed ID: 37390283
[TBL] [Abstract][Full Text] [Related]
40. The clinical value of conventional ultrasound combined with contrast-enhanced ultrasound in the evaluation of BI-RADS 4 lesions detected by magnetic resonance imaging.
Guo W; Li F; Jia C; Wang T; Zhang X; Yao G; Shi X; Bai M
Br J Radiol; 2022 Aug; 95(1136):20220025. PubMed ID: 35604699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
